• Posted on Tuesday, February 24, 2009
  • Bookmark and Share
  • email
  • |
  • print
  • |
  • rss

tool name

close
tool goes here

N.C. plant shipped tainted syringes that killed five people

email this story print this story jump to comments

Federal authorities are hunting the mastermind behind a "horrific case" in which bacteria-laden syringes shipped from an Angier plant sickened at least a hundred people and killed five.

Two men pleaded guilty Monday in U.S. District Court in Raleigh for their roles in ignoring sterility standards at the former AM2PAT Inc. plant. Conditions there appeared more consistent with a textile factory than a pharmaceutical facility.

The men – plant manager Aniruddha Patel and quality control director Ravindra Kumar Sharma – were each sentenced to 4 1/2 years in prison for fraud and allowing tainted drugs into the marketplace.

They were rewarded with a relatively light sentence in exchange for information about chief executive officer Dushyant Patel, whose company sold $6.9 million worth of heparin and saline syringes in 2006-07 that did not undergo proper sterility testing.

Dushyant Patel, indicted late last week on 10 charges that include fraud and selling adulterated medical devices, has not been arrested. Authorities think he may have fled to his homeland in India. They are seeking help from Interpol to find him.

To read the complete article, visit www.newsobserver.com.

  • Bookmark and Share
  • email
  • |
  • print
  • |
  • rss

tool name

close
tool goes here
JOIN THE DISCUSSION

We welcome comments. To post one, you must sign in using either your McClatchyDC login or your login for Facebook, Twitter or Disqus. Just click the appropriate box below.

Please keep your comment civil, short and to the point. Obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. If you find a comment abusive or inappropriate, please flag it for the moderator by placing your cursor on the comment, then clicking the "flag" link that appears. Thanks for your participation.

Stay Connected

Sign up for email newsletters RSS
Follow us on your iPhone Follow us on your Android device
Follow us on Facebook Follow us on Twitter Follow us using Google Currents